2seventy bio (NASDAQ:TSVT - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a report issued on Friday,Weiss Ratings reports.
2seventy bio Stock Performance
Shares of TSVT traded up $2.15 during mid-day trading on Friday, reaching $4.95. The stock had a trading volume of 31,459,760 shares, compared to its average volume of 955,059. The business has a fifty day moving average of $2.60 and a 200 day moving average of $3.68. 2seventy bio has a 12 month low of $2.29 and a 12 month high of $5.99. The firm has a market cap of $255.36 million, a price-to-earnings ratio of -2.66 and a beta of 1.73.
Institutional Trading of 2seventy bio
Several institutional investors and hedge funds have recently made changes to their positions in TSVT. Erste Asset Management GmbH bought a new stake in shares of 2seventy bio in the third quarter valued at about $25,000. Northern Trust Corp lifted its position in 2seventy bio by 1.4% during the fourth quarter. Northern Trust Corp now owns 408,083 shares of the company's stock valued at $1,200,000 after acquiring an additional 5,470 shares during the last quarter. Eversept Partners LP boosted its holdings in 2seventy bio by 0.6% in the fourth quarter. Eversept Partners LP now owns 1,003,678 shares of the company's stock worth $2,951,000 after acquiring an additional 5,599 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of 2seventy bio by 6.6% during the fourth quarter. American Century Companies Inc. now owns 93,552 shares of the company's stock worth $275,000 after purchasing an additional 5,785 shares during the period. Finally, Intech Investment Management LLC grew its position in 2seventy bio by 41.1% during the 4th quarter. Intech Investment Management LLC now owns 20,688 shares of the company's stock worth $61,000 after purchasing an additional 6,030 shares during the period. 93.90% of the stock is currently owned by institutional investors.
2seventy bio Company Profile
(
Get Free Report)
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Recommended Stories
Before you consider 2seventy bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 2seventy bio wasn't on the list.
While 2seventy bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
